The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells

被引:25
作者
Baptiste N. [1 ]
Friedlander P. [1 ]
Chen X. [1 ]
Prives C. [1 ]
机构
[1] Department of Biological Sciences, Columbia University, New York
关键词
Anti-neoplastics; Apoptosis; p53; Proline-rich domain;
D O I
10.1038/sj.onc.1205015
中图分类号
学科分类号
摘要
In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracycline-regulated promoter. In these cells the induction of wild-type p53 leads to significant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sufficient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also effectively increase cell death when a transcriptionally-defective p53, p53[gln22ser23], is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53[gln22ser23]. Our results with 5-FU thus show that genetically separable functions of p53 are involved in its ability to respond to DNA-damaging agents to induce apoptosis. Notably as well, deleting the C-terminal 30 amino acids of p53 does not affect this cooperative effect with DNA-damaging agents. By contrast, a p53 mutant lacking the PXXP-domain between residues 60-90, while at least partially transcriptionally-competent, cannot be rendered apoptotic by any compounds that we tested. Thus the PXXP domain provides an essential component of the ability of p53 to respond to DNA-damaging agents to cause cell death.
引用
收藏
页码:9 / 21
页数:12
相关论文
共 115 条
  • [1] Appella E., Anderson C.W., Pathol. Biol. (Paris), 48, pp. 227-245, (2000)
  • [2] Appella A., Eur. J. Biochem., 268, (2001)
  • [3] Asada M., Yamada T., Ichijo H., Delia D., Miyazono K., Fukumuro K., Mizutani S., EMBO J., 18, pp. 1223-1234, (1999)
  • [4] Attardi L.D., Lowe S.W., Brugarolas J., Jacks T., EMBO J., 15, pp. 3693-3701, (1996)
  • [5] Attardi L.D., Jacks T., Cell. Mol. Life Sci., 55, pp. 48-63, (1999)
  • [6] Avantaggiati M.L., Ogryzko V., Gardner K., Giordano A., Levine A.S., Kelly K., Cell, 89, pp. 1175-1184, (1997)
  • [7] Bakalkin G., Selivanova G., Yakovleva T., Kiseleva E., Kashuba E., Magnusson K.P., Szekely L., Klein G., Terenius L., Wiman K.G., Nucleic Acids Res., 23, pp. 362-369, (1995)
  • [8] Banin S., Moyal L., Shieh S., Taya Y., Anderson C.W., Chessa L., Smorodinsky N.I., Prives C., Reiss Y., Shiloh Y., Ziv Y., Science, 281, pp. 1674-1677, (1998)
  • [9] Bayle J.H., Elenbaas B., Levine A.J., Proc. Natl. Acad. Sci. USA, 92, pp. 5729-5733, (1995)
  • [10] Bennett M., Macdonald K., Chan S.W., Luzio J.P., Simari R., Weissberg P., Science, 282, pp. 290-293, (1998)